fosfomycin IV
Selected indexed studies
- Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature. (J Antimicrob Chemother, 2024) [PMID:39215642]
- IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. (J Antimicrob Chemother, 2021) [PMID:33855449]
- Subcutaneously administered antibiotics: a review. (J Antimicrob Chemother, 2022) [PMID:36374566]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases. (2024) pubmed
- Subcutaneously administered antibiotics: a review. (2022) pubmed
- Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature. (2024) pubmed
- IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. (2021) pubmed
- Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. (2019) pubmed
- Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review. (2025) pubmed
- Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. (2023) pubmed
- Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry. (2023) pubmed
- Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections. (2024) pubmed
- Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens? (2019) pubmed